Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/JAMP RIVASTIGMINE

Authorized

STANDARD

JAMP RIVASTIGMINE

Jamp Pharma Corporation🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: b284ee6e0f3c5a37
Company: Jamp Pharma Corporation
Type: Standard

Approval Details

Approval Id: b284ee6e0f3c5a37
Drug Approval Canada Name: JAMP RIVASTIGMINE
Product Name: JAMP RIVASTIGMINE
Status: Marketed
Status Date: 2020-02-10
Original Market Date: 2020-02-10
Din: 02485389
Drug Class: Human
Dosage Form: Capsule
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 12:04.00
Atc Original: N06DA03 RIVASTIGMINE
Atc Name: n 06 da 03
Aig Number: 0140521003
Company Name: Jamp Pharma Corporation
Company Address: 1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Company Detail Path: /organization/jamp-pharma-corporation

Company Information

Pharmaceutical Company Name: Jamp Pharma Corporation
Country Name: Canada
Province Name: British Columbia
City Name: chilliwack,british columbia,country_ca
Address: 8065 Aitken Rd

Active Ingredients

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)

4.5 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

b284ee6e0f3c5a37

Type

Standard

Back to Health Canada Approvals

JAMP RIVASTIGMINE - Health Canada Drug Approval Details